<DOC>
	<DOCNO>NCT00109057</DOCNO>
	<brief_summary>This multicenter , open-label extension study . Subjects receive rhuMAb VEGF ( Avastin ) therapy Genentech-sponsored Phase I Phase II cancer study show evidence disease progression completion parent study eligible inclusion trial .</brief_summary>
	<brief_title>An Extension Study Evaluate Avastin Patients Treated Previous Genentech-Sponsored Cancer Study</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Previous participation completion Genentechsponsored rhuMAb VEGF Phase I Phase II cancer study No evidence progressive disease completion parent study For woman childbearing potential , use effective mean contraception Signed informed consent Any unresolved irreversible rhuMAb VEGFrelated ongoing serious adverse event occur parent study Any history central nervous system disease ( e.g. , primary brain tumor seizure within 12 month first infusion study ) , and/or evidence brain metastasis Compromised renal hepatic function , define parent protocol Anemia , neutropenia , thrombocytopenia , define parent protocol Pregnancy ( positive pregnancy test ) lactation Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored rhuMAb VEGF cancer study Recent ( within 3 week first infusion study ) major surgical procedure , biopsy parenchymal organ , significant traumatic injury Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension [ blood pressure &gt; 160/110 mmHg medication ] , myocardial infarction , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac dysrhythmia require medication , peripheral vascular disease ( Grade II great ) Serious , nonhealing wound , ulcer , bone fracture Current recent ( within 10 day first infusion study ) use oral parenteral anticoagulant aspirin ( except require maintain patency permanent indwell intravenous [ IV ] catheter ) Inability comply study and/or followup procedure History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced malignancy</keyword>
</DOC>